Search

Your search keyword '"Daures, J. P."' showing total 40 results
Start Over Author "Daures, J. P." Search Limiters Available in Library Collection
40 results on '"Daures, J. P."'

5. High energy photon reference for radiation protection: technical design of the LINAC beam and ionization chambers; and calculation of monoenergetic conversion coefficients

Author

Dusciac D., Bordy J.-M., Daures J., and Blideanu V.

Subjects
Physics, QC1-999
Abstract

In this work, we present the results of the first part of a research project aimed at offering a complete response to dosimeters providers and nuclear physicists’ demands for high-energy (6 – 9 MeV) photon beams for radiation protection purposes. Classical facilities allowing the production of high-energy photonic radiation (proton accelerators, nuclear reactors) are very rare and need large investment for development and use. A novel solution is proposed, consisting in the use of a medical linear accelerator, allowing a significant decrease of all costs.Using Monte Carlo simulations (MCNP5 and PENELOPE codes), a specifically designed electron-photon conversion target allowing for obtaining a high energy photon beam (with an average energy weighted by fluence of about 6 MeV) has been built for radiation protection purposes. Due to the specific design of the target, this “realistic” radiation protection high-energy photon beam presents a uniform distribution of air kerma rate at a distance of 1 m, over a 30 × 30 cm2 surface. Two graphite cavity ionizing chambers for ionometric measurements have been built. For one of these chambers, the charge collection volume has been measured allowing for its use as a primary standard. The second ionizing chamber is used as a transfer standard; as such it has been calibrated in a 60Co beam, and in the high energy photon beam for radiation protection.The measurements with these ionizing chambers allowed for an evaluation of the air kerma rate in the LINAC based high-energy photon beam for radiation protection: the values cover a range between 36 mGy/h and 210 mGy/h, compatible with radiation protection purposes.Finally, using Monte Carlo simulations, conversion coefficients from air kerma to dose equivalent quantities have been calculated in the range between 10 keV and 22.4 MeV, for the spectral distribution of the fluence corresponding to the beam produced by the linear accelerator of the LNE-LNHB.

Published
2016
Full Text
View/download PDF

12. Can power Doppler ultrasound of the entheses help in classifying recent axial spondyloarthritis? Data from the DESIR cohort

Author

Poulain, C., D'Agostino, M. A., Thibault, S., Daures, J. P., Ferkal, S., Le Corvoisier, P., Rahmouni, A., Loeuille, D., Dougados, M., Claudepierre, P., D'Agostino M. A. (ORCID:0000-0002-5347-0060), Poulain, C., D'Agostino, M. A., Thibault, S., Daures, J. P., Ferkal, S., Le Corvoisier, P., Rahmouni, A., Loeuille, D., Dougados, M., Claudepierre, P., and D'Agostino M. A. (ORCID:0000-0002-5347-0060)

Abstract

Early diagnosis of axial spondyloarthritis (axSpA) remains a challenge due to the lack of specificity of clinical symptoms and variable prevalence of axial imaging findings permitting a definite diagnosis. Power Doppler ultrasonography (PDUS) of the entheses has demonstrated to be a potential useful tool for the classification and diagnostic management of early SpA independently of the phenotype. Objectives To assess the classification value (sensitivity and specificity) of PDUS-defined enthesitis for identifying patients fulfilling Assessment of SpondyloArthritis international Society (ASAS) classification criteria for axSpA (ASAS+) in patients with recent inflammatory back pain (IBP) (the DESIR (DEvenir des Spondylarthropathies Indifférenciées Récentes) cohort). Methods Baseline PDUS was performed at eight entheseal sites, and PDUS enthesitis was defined by the presence of vascularisation at entheseal insertion. Results 402 patients from the DESIR cohort underwent a PDUS evaluation. PDUS enthesitis was detected in 58 (14.4%) patients of whom 40 (14.2%) belonged to the ASAS+ patients and 18 (17%) to the ASAS- patients. The sensitivity of PDUS enthesitis was 13.9% and the specificity was 83.5%, with a positive predictive value of 69% and 26.8% of negative predictive value for meeting ASAS criteria for axSpA. Of the 18 ASAS- patients with positive PDUS, 59% fulfilled Amor's criteria, 88% European Spondyloarthropathy Study Group criteria and 59% both. Conclusions In a cohort of patients with recent IBP, the prevalence of PDUS enthesitis was low (14.4%); however, its specificity for classifying patients as axSpA according to ASAS criteria was high (83.5%). PDUS enthesitis might be of additional value for classifying as patients with axSpA IBP who do not fulfil ASAS criteria.

Published
2018

13. Opportunistic infections and AIDS malignancies early after initiating combination antiretroviral therapy in high-income countries

Author

Lodi, Sara, Del Amo, Julia, Moreno, Santiago, Bucher, H. C., Furrer, Hansjakob, Logan, Roger, Sterne, Jonathan, Pérez-Hoyos, Santiago, Jarrín, Inma, Phillips, Andrew, Olson, Ashley, Van Sighem, Ard, Reiss, Peter, Sabin, C., Jose, Sophie, Justice, Amy, Goulet, Joseph, Miró, José M., Ferrer, Elena, Meyer, Laurence, Seng, Rémonie, Vourli, Georgia, Antoniadou, Anastasia, Dabis, Francois, Vandenhede, Mari Anne, Costagliola, Dominique, Abgrall, S., Hernán, Miguel A., Hernan, Miguel, Bansi, L., Hill, T., Dunn, D., Porter, K., Glabay, A., Orkin, C., Thomas, R., Jones, K., Fisher, M., Perry, N., Pullin, A., Churchill, D., Gazzard, B., Nelson, M., Asboe, D., Bulbeck, S., Mandalia, S., Clarke, J., Delpech, V., Anderson, J., Munshi, S., Post, F., Easterbrook, P., Khan, Y., Patel, P., Karim, F., Duffell, S., Gilson, R., Man, S. L., Williams, I., Gompels, M., Dooley, D., Schwenk, A., Ainsworth, J., Johnson, M., Youle, M., Lampe, F., Smith, C., Grabowska, H., Chaloner, C., Ismajani Puradiredja, D., Phillips, A., Walsh, J., Weber, J., Kemble, C., Mackie, N., Winston, A., Leen, C., Wilson, A., Bezemer, D. O., Gras, L. A.J., Kesselring, A. M., Van Sighem, A. I., Zaheri, S., Van Twillert, G., Kortmann, W., Branger, J., Prins, J. M., Kuijpers, T. W., Scherpbier, H. J., Van Der Meer, J. T.M., Wit, F. W.M.N., Godfried, M. H., Reiss, P., Van Der Poll, T., Nellen, F. J.B., Lange, J. M.A., Geerlings, S. E., Van Vugt, M., Pajkrt, D., Bos, J. C., Van Der Valk, M., Grijsen, M. L., Wiersinga, W. J., Brinkman, K., Blok, W. L., Frissen, P. H.J., Schouten, W. E.M., Van Den Berk, G. E.L., Veenstra, J., Lettinga, K. D., Mulder, J. W., Vrouenraets, S. M.E., Lauw, F. N., Van Eeden, A., Verhagen, D. W.M., Van Agtmael, M. A., Perenboom, R. M., Claessen, F. A.P., Bomers, M., Peters, E. J.G., Richter, C., Van Der Berg, J. P., Gisolf, E. H., Schippers, E. F., Van Nieuwkoop, C., Van Elzakker, E. P., Leyten, E. M.S., Gelinck, L. B.S., Pronk, M. J.H., Bravenboer, B., Kootstra, G. J., Delsing, C. E., Sprenger, H. G., Doedens, R., Scholvinck, E. H., Van Assen, S., Bierman, W. F.W., Soetekouw, R., Ten Kate, R. W., Van Vonderen, M. G.A., Van Houte, D. P.F., Kroon, F. P., Van Dissel, J. T., Arend, S. M., De Boer, M. G.J., Jolink, H., Ter Vollaard, H. J.M., Bauer, M. P., Weijer, S., El Moussaoui, R., Lowe, S., Schreij, G., Oude Lashof, A., Posthouwer, D., Koopmans, P. P., Keuter, M., Van Der Ven, A. J.A.M., Ter Hofstede, H. J.M., Dofferhoff, A. S.M., Warris, A., Van Crevel, R., Van Der Ende, M. E., De Vries-Sluijs, T. E.M.S., Schurink, C. A.M., Nouwen, J. L., Nispen Tot Pannerden, M. H., Verbon, A., Rijnders, B. J.A., Van Gorp, E. C.M., Hassing, R. J., Smeulders, A. W.M., Hartwig, N. G., Driessen, G. J.A., Den Hollander, J. G., Pogany, K., Juttmann, J. R., Van Kasteren, M. E.E., Hoepelman, A. I.M., Mudrikova, T., Schneider, M. M.E., Jaspers, C. A.J.J., Ellerbroek, P. M., Oosterheert, J. J., Arends, J. E., Wassenberg, M. W.M., Barth, R. E., Geelen, S. P.M., Wolfs, T. F.W., Bont, L. J., Van Den Berge, M., Stegeman, A., Groeneveld, P. H.P., Alleman, M. A., Bouwhuis, J. W., Barin, F., Burty, C., Duvivier, C., Enel, P., Fredouille-Heripret, L., Gasnault, J., Khuong, M. A., Mahamat, A., Pilorgé, F., Tattevin, P., Salomon, Valérie, Jacquemet, N., Costagliola, D., Grabar, S., Guiguet, M., Lanoy, E., Lièvre, L., Mary-Krause, M., Selinger-Leneman, H., Lacombe, J. M., Potard, V., Bricaire, F., Herson, S., Katlama, C., Simon, A., Desplanque, N., Girard, P. M., Meynard, J. L., Meyohas, M. C., Picard, O., Cadranel, J., Mayaud, C., Pialoux, G., Clauvel, J. P., Decazes, J. M., Gérard, L., Molina, J. M., Diemer, M., Sellier, P., Bentata, M., Honoré, P., Jeantils, V., Tassi, S., Mechali, D., Taverne, B., Bouvet, E., Crickx, B., Ecobichon, J. L., Matheron, S., Picard-Dahan, C., Yeni, P., Berthé, H., Dupont, C., Chandemerle, C., Mortier, E., De Truchis, P., Tisne-Dessus, D., Weiss, L., Salmon, D., Auperin, I., Gilquin, J., Roudière, L., Viard, J. P., Boue, F., Fior, R., Delfraissy, J. F., Goujard, C., Jung, C., Lesprit, Ph, Vittecoq, D., Fraisse, P., Lang, J. M., Rey, D., Beck-Wirth, G., Stahl, J. P., Lecercq, P., Gourdon, F., Laurichesse, H., Fresard, A., Lucht, F., Bazin, C., Verdon, R., Chavanet, P., Arvieux, C., Michelet, C., Choutet, P., Goudeau, A., Maître, M. F., Hoen, B., Eglinger, P., Faller, J. P., Borsa-Lebas, F., Caron, F., Reynes, J., Daures, J. P., May, T., Rabaud, C., Berger, J. L., Rémy, G., Arlet-Suau, E., Cuzin, L., Massip, P., Thiercelin Legrand, M. F., Pontonnier, G., Viget, N., Yasdanpanah, Y., Dellamonica, P., Pradier, C., Pugliese, P., Aleksandrowicz, K., Quinsat, D., Ravaux, I., Tissot-Dupont, H., Delmont, J. P., Moreau, J., Gastaut, J. A., Poizot Martin, I., Retornaz, F., Soubeyrand, J., Galinier, A., Ruiz, J. M., Allegre, T., Blanc, P. A., Bonnet-Montchardon, D., Lepeu, G., Granet-Brunello, P., Esterni, J. P., Pelissier, L., Cohen-Valensi, R., Nezri, M., Chadapaud, S., Laffeuillade, A., Billaud, E., Raffi, F., Boibieux, A., Peyramond, D., Livrozet, J. M., Touraine, J. L., Cotte, L., Trepo, C., Strobel, M., Bissuel, F., Pradinaud, R., Sobesky, M., Cabié, A., Gaud, C., Contant, M., Aubert, V., Barth, J., Battegay, M., Bernasconi, E., Böni, J., Burton-Jeangros, C., Calmy, A., Cavassini, M., Egger, M., Elzi, L., Fehr, J., Fellay, J., Furrer, H., Haerry, D., Fux, C. A., Gorgievski, M., Günthard, H., Hasse, B., Hirsch, H. H., Hösli, I., Kahlert, C., Kaiser, L., Keiser, O., Klimkait, T., Kovari, H., Ledergerber, B., Martinetti, G., Martinez De Tejada, B., Metzner, K., Müller, N., Nadal, D., Pantaleo, G., Rauch, A., Regenass, S., Rickenbach, M., Rudin, C., Schmid, P., Schultze, D., Schöni-Affolter, F., Schüpbach, J., Speck, R., Taffé, P., Tarr, P., Telenti, A., Trkola, A., Vernazza, P., Weber, R., Yerly, S., Casabona, J., Gallois, A., Esteve, A., Podzamczer, D., Murillas, J., Gatell, J. M., Manzardo, C., Tural, C., Clotet, B., Ferrer, E., Riera, M., Segura, F., Navarro, G., Force, L., Vilaró, J., Masabeu, A., García, I., Guadarrama, M., Cifuentes, C., Dalmau, D., Jaen, Agustí, C., Montoliu, A., Pérez, I., Gargoulas, Freyra, Blanco, J. L., Garcia-Alcaide, F., Martínez, E., Mallolas, J., López-Dieguez, M., García-Goez, J. F., Sirera, G., Romeu, J., Jou, A., Negredo, E., Miranda, C., Capitan, M. C., Saumoy, M., Imaz, A., Tiraboschi, J. M., Murillo, O., Bolao, F., Peña, C., Cabellos, C., Masó, M., Vila, A., Sala, M., Cervantes, M., Jose Amengual, Ma, Navarro, M., Penelo, E., Barrufet, P., Bejarano, G., Molina, J., Alvaro, M., Mercadal, J., Fernandez, Juanse, Ospina, Jesus E., Muñoz, M. A., Caro-Murillo, A. M., Sobrino, P., Jarrín, I., Gomez Sirvent, J. L., Rodríguez, P., Aleman, M. R., Alonso, M. M., Lopez, A. M., Hernandez, M. I., Soriano, V., Labarga, P., Barreiro, P., Medrano, J., Rivas, P., Herrero, D., Blanco, F., Vispo, M. E., Martín, L., Ramírez, G., De Diego, M., Rubio, R., Pulido, F., Moreno, V., Cepeda, C., Hervás, Rl, Iribarren, J. A., Arrizabalaga, J., Aramburu, M. J., Camino, X., Rodrí-guez-Arrondo, F., Von Wichmann, M. A., Pascual, L., Goenaga, M. A., Gutierrez, F., Masia, M., Ramos, J. M., Padilla, S., Sanchez-Hellín, V., Bernal, E., Escolano, C., Montolio, F., Peral, Y., Berenguer, J., Lopez, J. C., Miralles, P., Cosín, J., Sanchez, M., Gutierrez, I., Ramírez, M., Padilla, B., Vidal, F., Sanjuan, M., Peraire, J., Veloso, S., Vilades, C., Lopez-Dupla, M., Olona, M., Vargas, M., Aldeguer, J. L., Blanes, M., Lacruz, J., Salavert, M., Montero, M., Cuéllar, S., De Los Santos, I., Sanz, J., Oteo, J. A., Blanco, J. R., Ibarra, V., Metola, L., Sanz, M., Pérez-Martínez, L., Sola, J., Uriz, J., Castiello, J., Reparaz, J., Arriaza, M. J., Irigoyen, C., Moreno, S., Antela, A., Casado, J. L., Dronda, F., Moreno, A., Pérez, M. J., López, D., Gutiérrez, C., Hernández, B., Pumares, M., Martí, P., García, L., Page, C., García, F., Hernández, J., Peña, A., Muñoz, L., Parra, J., Viciana, P., Leal, M., López-Cortés, L. F., Trastoy, M., Mata, R., Justice, A. C., Fiellin, D. A., Rimland, D., Jones-Taylor, C., Oursler, K. A., Titanji, R., Brown, S., Garrison, S., Rodriguez-Barradas, M., Masozera, N., Goetz, M., Leaf, D., Simberkoff, M., Blumenthal, D., Leung, J., Butt, A., Hoffman, E., Gibert, C., Peck, R., Mattocks, K., Braithwaite, S., Brandt, C., Bryant, K., Cook, R., Conigliaro, J., Crothers, K., Chang, J., Crystal, S., Day, N., Erdos, J., Freiberg, M., Kozal, M., Gandhi, N., Gaziano, M., Gerschenson, M., Good, B., Gordon, A., Goulet, J. L., Hernán, M. A., Kraemer, K., Lim, J., Maisto, S., Miller, P., Mole, L., O'Connor, P., Papas, R., Robins, J. M., Rinaldo, C., Roberts, M., Samet, J., Tierney, B., Whittle, J., Babiker, A., Brettle, R., Darbyshire, J., Goldberg, D., Hawkins, D., Jaffe, H., Johnson, A., McLean, K., Pillay, D., Cursley, Adam, Ewings, Fiona, Fairbrother, Keith, Louisa Gnatiuc, S. L., Murphy, Brendan, Douglas, G., Kennedy, N., Pritchard, J., Andrady, U., Rajda, N., Maw, R., McKernan, S., Drake, S., Gilleran, G., White, D., Ross, J., Toomer, S., Hewart, R., Wilding, H., Woodward, R., Dean, G., Heald, L., Horner, P., Glover, S., Bansaal, D., Eduards, S., Carne, C., Browing, M., Das, R., Stanley, B., Estreich, S., Magdy, A., O'Mahony, C., Fraser, P., Hayman, B., Jebakumar, S. P.R., Joshi, U., Ralph, S., Wade, A., Mette, R., Lalik, J., Summerfield, H., El-Dalil, A., France, J. A., White, C., Robertson, R., Gordon, S., McMillan, S., Morris, S., Lean, C., Vithayathil, K., McLean, L., Winter, A., Gale, D., Jacobs, S., Tayal, S., Short, L., Green, S., Williams, G., Sivakumar, K., Bhattacharyya, N. D., Monteiro, E., Minton, J., Dhar, J., Nye, F., De Souza, C. B., Isaksen, A., McDonald, L., Franca, A., William, L., Jendrulek, I., Peters, B., Shaunak, S., El-Gadi, S., Easterbrook, P. J., Mazhude, C., Johnstone, R., Fakoya, A., McHale, J., Waters, A., Kegg, S., Mitchell, S., Byrne, P., Rice, P., Fidler, S., Mullaney, S. A., McCormack, S., David, D., Melville, R., Phillip, K., Balachandran, T., Mabey-Puttock, S., Sukthankar, A., Murphy, C., Wilkins, E., Ahmad, S., Haynes, J., Evans, E., Ong, E., Grey, R., Meaden, J., Bignell, C., Loay, D., Peacock, K., Girgis, M. R., Morgan, B., Palfreeman, A., Wilcox, J., Tobin, J., Tucker, L., Saeed, A. M., Chen, F., Deheragada, A., Williams, O., Lacey, H., Herman, S., Kinghorn, D., Devendra, V. S., Wither, J., Dawson, S., Rowen, D., Harvey, J., Bridgwood, A., Singh, G., Chauhan, M., Kellock, D., Young, S., Dannino, S., Kathir, Y., Rooney, G., Currie, J., FitzGerald, M., Devendra, S., Keane, F., Booth, G., Green, T., Arumainayyagam, J., Chandramani, S., Rajamanoharan, S., Robinson, T., Curless, E., Gokhale, R., Tariq, A., Luzzi, G., Fairley, I., Wallis, F., Smit, E., Ward, F., Loze, B., Morlat, P., Bonarek, M., Bonnet, F., Nouts, C., Louis, I., Reliquet, V., Sauser, F., Biron, C., Mounoury, O., Hue, H., Brosseau, D., Ghosn, J., Rannou, M. T., Bergmann, J. F., Badsi, E., Rami, A., Parrinello, M., Samanon-Bollens, D., Campa, P., Tourneur, M., Desplanques, N., Jeanblanc, F., Chiarello, P., Makhloufi, D., Blanc, A. P., Allègre, T., Baillat, V., Lemoing, V., Merle De Boever, C., Tramoni, C., Sobesky, G., Abel, S., Beaujolais, V., Slama, L., Chakvetadze, C., Berrebi, V., Fournier, I., Gerbe, J., Koffi, K., Augustin-Normand, C., Miailhes, P., Thoirain, V., Brochier, C., Souala, F., Ratajczak, M., Beytoux, J., Jacomet, C., Rouveix, E., Morelon, S., Olivier, C., Lortholary, O., Dupont, B., Maignan, A., Ragnaud, J. M., Raymond, I., Leport, C., Jadand, C., Jestin, C., Longuet, P., Boucherit, S., Sereni, D., Lascoux, C., Prevoteau, F., Sobel, A., Levy, Y., Lelievre, J. D., Lascaux, A. S., Dominguez, S., Dumont, C., Aumâitre, H., Delmas, B., Saada, M., Medus, M., Guillevin, L., Tahi, T., Yazdanpanah, Y., Pavel, S., Marien, M. C., Drenou, B., Beck, C., Benomar, M., Tubiana, R., Ait Mohand, H., Chermak, A., Ben Abdallah, S., Touam, F., Drobacheff, C., Folzer, A., Obadia, M., Prudhomme, L., Bonnet, E., Balzarin, F., Pichard, E., Chennebault, J. M., Fialaire, P., Loison, J., Galanaud, P., Boué, F., Bornarel, D., Six, M., Ferret, P., Batisse, D., Gonzales-Canali, G., Devidas, A., Chevojon, P., Turpault, I., Lafeuillade, A., Cheret, A., Philip, G., Morel, P., Timsit, J., Amirat, N., Brancion, C., Cabane, J., Tredup, J., Stein, A., Ravault, I., Chavanet, C., Buisson, M., Treuvetot, S., Nau, P., Bastides, F., Boyer, L., Wassoumbou, S., Oksenhendeler, E., Bernard, L., Domart, Y., Merrien, D., Greder Belan, A., Gayraud, M., Bodard, L., Meudec, A., Beuscart, C., Daniel, C., Pape, E., Vinceneux, P., Simonpoli, A. M., Zeng, A., Fournier, L., Fuzibet, J. G., Sohn, C., Rosenthal, E., Quaranta, M., Chaillou, S., Sabah, M., Audhuy, B., Schieber, A., Moreau, P., Niault, M., Vaillant, O., Huchon, G., Compagnucci, A., De Lacroix Szmania, I., Richier, L., Lamaury, I., Saint-Dizier, F., Garipuy, D., Drogoul, M. P., Fabre, G., Lambert De Cursay, G., Abraham, B., Perino, C., Lagarde, P., David, F., Roche-Sicot, J., Saraux, J. L., Leprêtre, A., Fampin, B., Uludag, A., Morin, A. S., Bletry, O., Zucman, D., Regnier, A., Girard, J. J., Quinsat, D. T., Heripret, L., Grihon, F., Houlbert, D., Ruel, M., Chemlal, K., Debab, Y., Tremollieres, F., Perronne, V., Slama, B., Perré, P., Miodovski, C., Guermonprez, G., Dulioust, A., Boudon, P., Malbec, D., Patey, O., Semaille, C., Deville, J., Remy, G., Béguinot, I., Chambrin, V., Pignon, C., Estocq, G. A., Levy, A., Duracinsky, M., Le Bras, P., Ngussan, M. S., Peretti, D., Medintzeff, N., Lambert, T., Segeral, O., Lezeau, P., Laurian, Y., Piketty, C., Karmochkine, M., Eliaszewitch, M., Jayle, D., Kazatchkine, M., Colasante, U., Duval, X., Nouaouia, W., Vilde, J. L., Bollens, D., Binet, D., Diallo, B., Fonquernie, L., Lagneau, J. L., Launay, O., Pietrie, M. P., Sicard, D., Stieltjes, N., Michot, J., Bourdillon, F., Obenga, G., Escaut, L., Bolliot, C., Schneider, L., Iguertsira, M., Tomei, C., Dhiver, C., Tissot Dupont, H., Vallon, A., Gallais, J., Gallais, H., Durant, J., Mondain, V., Perbost, I., Cassuto, J. P., Karsenti, J. M., Venti, H., Ceppi, C., Krivitsky, J. A., Bouchaud, O., Honore, P., Delgado, J., Rouzioux, C., Burgard, M., Boufassa, L., Peynet, J., Pérez-Hoyos, S., Del Amo, J., Alvarez, D., Monge, S., Muga, R., Sanvisens, A., Tor, J., Rivas, I., Vallecillo, G., Del Romero, J., Raposo, P., Rodríguez, C., Vera, M., Hurtado, I., Belda, J., Fernandez, E., Alastrue, I., Santos, C., Tasa, T., Juan, A., Trullen, J., Garcia De Olalla, P., Cayla, J., Masdeu, E., Knobel, H., Mirò, J. M., Sambeat, M. A., Guerrero, R., Rivera, E., Marco, A., Quintana, M., Gonzalez, C., Castilla, J., Guevara, M., De Mendoza, C., Zahonero, N., Ortíz, M., Paraskevis, D., Touloumi, G., Pantazis, N., Bakoyannis, G., Gioukari, V., Antoniadou, A., Papadopoulos, A., Petrikkos, G., Daikos, G., Psichogiou, M., Gargalianos-Kakolyris, P., Xylomenos, G., Katsarou, O., Kouramba, A., Ioannidou, P., Kordossis, T., Kontos, A., Lazanas, M., Chini, M., Tsogas, N., Panos, G., Paparizos, V., Leuow, K., Kourkounti, S., Sambatakou, H., Mariolis, I., Skoutelis, A., Papastamopoulos, V., Baraboutis, I., Internal medicine, APH - Aging & Later Life, Pediatric surgery, CCA - Innovative therapy, ICaR - Circulation and metabolism, ICaR - Ischemia and repair, Graduate School, Paediatric Infectious Diseases / Rheumatology / Immunology, Landsteiner Laboratory, AII - Amsterdam institute for Infection and Immunity, Infectious diseases, Global Health, Center of Experimental and Molecular Medicine, APH - Amsterdam Public Health, AII - Inflammatory diseases, and ARD - Amsterdam Reproduction and Development

Subjects
Adult, Male, medicine.medical_specialty, Adolescent, Opportunistic infection, AIDS-Related Opportunistic Infections, Immunology, Population, Retinitis, HIV Infections, Article, 17 Psychology And Cognitive Sciences, Young Adult, Immune reconstitution inflammatory syndrome, Antiretroviral Therapy, Highly Active, Neoplasms, Virology, Internal medicine, medicine, Humans, Immunology and Allergy, education, Inverse probability weighting, Aged, education.field_of_study, business.industry, Developed Countries, Incidence, Progressive multifocal leukoencephalopathy, Hazard ratio, HIV, virus diseases, 11 Medical And Health Sciences, Middle Aged, 06 Biological Sciences, medicine.disease, United States, Europe, Infectious Diseases, Anti-Retroviral Agents, Unmasking, Female, Cytomegalovirus retinitis, business
Abstract

Background: There is little information on the incidence of AIDS-defining events which have been reported in the literature to be associated with immune reconstitution inflammatory syndrome (IRIS) after combined antiretroviral therapy (cART) initiation. These events include tuberculosis, mycobacterium avium complex (MAC), cytomegalovirus (CMV) retinitis, progressive multifocal leukoencephalopathy (PML), herpes simplex virus (HSV), Kaposi sarcoma, non-Hodgkin lymphoma (NHL), cryptococcosis and candidiasis.Methods: We identified individuals in the HIV-CAUSAL Collaboration, which includes data from six European countries and the US, who were HIV-positive between 1996 and 2013, antiretroviral therapy naive, aged at least 18 years, hadCD4+ cell count and HIV-RNA measurements and had been AIDS-free for at least 1 month between those measurements and the start of follow-up. For each AIDS-defining event, we estimated the hazard ratio for no cART versus less than 3 and at least 3 months since cART initiation, adjusting for time-varying CD4+ cell count and HIV-RNA via inverse probability weighting.Results: Out of 96 562 eligible individuals (78% men) with median (interquantile range) follow-up of 31 [13,65] months, 55 144 initiated cART. The number of cases varied between 898 for tuberculosis and 113 for PML. Compared with non-cART initiation, the hazard ratio (95% confidence intervals) up to 3 months after cART initiation were 1.21 (0.90-1.63) for tuberculosis, 2.61 (1.05-6.49) for MAC, 1.17 (0.34-4.08) for CMV retinitis, 1.18 (0.62-2.26) for PML, 1.21 (0.83-1.75) for HSV, 1.18 (0.87-1.58) for Kaposi sarcoma, 1.56 (0.82-2.95) for NHL, 1.11 (0.56-2.18) for cryptococcosis and 0.77 (0.40-1.49) for candidiasis.Conclusion: With the potential exception of mycobacterial infections, unmasking IRIS does not appear to be a common complication of cART initiation in high-income countries.

Published
2014

14. Clinical presentation of patients suffering from recent onset chronic inflammatory back pain suggestive of spondyloarthritis: The DESIR cohort

Author

Dougados, M., Etcheto, A., Molto, A., Alonso, S., Bouvet, S., Daures, J. -P., Landais, P., d'Agostino, M. A., Berenbaum, F., Breban, M., Claudepierre, P., Combe, B., Fautrel, B., Feydy, A., Goupille, P., Richette, P., Pham, T., Roux, C., Treluyer, J. -M., Saraux, A., van der Heijde, D., Wendling, D., d'Agostino M. A. (ORCID:0000-0002-5347-0060), Dougados, M., Etcheto, A., Molto, A., Alonso, S., Bouvet, S., Daures, J. -P., Landais, P., d'Agostino, M. A., Berenbaum, F., Breban, M., Claudepierre, P., Combe, B., Fautrel, B., Feydy, A., Goupille, P., Richette, P., Pham, T., Roux, C., Treluyer, J. -M., Saraux, A., van der Heijde, D., Wendling, D., and d'Agostino M. A. (ORCID:0000-0002-5347-0060)

Abstract

Objectives: DESIR is a prospective longitudinal multicentric French cohort of patients with inflammatory back pain suggestive of spondyloarthritis, with a 10-year-follow-up. The purpose is to evaluate the performances of the different sets of classification criteria for axial spondyloarthritis, and to describe the frequency and characteristics of the clinical features of axial spondyloarthritis. Methods: Demographic data and items allowing classification and indices calculation were collected, as well as biologic and imaging data. Baseline data are analyzed. The performance of the several classification criteria sets was evaluated (likelihood ratio) with the physician's diagnosis as external gold standard. For the clinical presentation of axial spondyloarthritis, a descriptive analysis was conducted. Results: Seven hundred and eight patients are included. Ninety-two percent of them satisfy at least one set of classification criteria: mNY 26%, Amor 79%, ESSG 78%, ASAS 70%; physician's confidence level 6.8 ± 2.7. 81 and 83% of patients fulfil modified (including MRI) Amor or ESSG criteria. Axial involvement is present in 100% of the cases. NSAIDs are taken by 90%, with an NSAID sore of 50 ± 46. BASDAI over 40 is noted in 60% and elevated CRP in 30% of the cases. HLA-B27 is present in 58%. According to ASDAS CRP levels, 12.7% are in inactive disease, 63% in high disease activity; mean BASFI was 30. Peripheral involvement is present in 57%, with arthritis in 37% of these. Enthesitis is noted in 49% of the patients, and first symptom in 22.5%; anterior chest wall involvement is noted in 44.6%, and dactylitis in 13%. For extra articular manifestations, psoriasis is recorded in 16%, uveitis in 8.5% and IBD in 5.1%. Smoking is present in 36.3% and hypertension in 5.1% of the cases. Conclusion: These data represent the base of evaluation of the follow-up of this cohort, allowing future specific studies.

Published
2015

15. HLA-DRB1 genes and patients with late onset rheumatoid arthritis

Author

Hellier, J-P, Eliaou, J-F, Daures, J-P, Sany, J, and Combe, B

Subjects
HLA class II antigens -- Health aspects, Disease susceptibility -- Genetic aspects, Rheumatoid arthritis -- Genetic aspects, Health, Genetic aspects, Health aspects
Abstract

Abstract Objective--To determine the influence of HLA-DRB*1 genes on susceptibility to and severity of rheumatoid arthritis (RA) in patients with late onset compared with younger onset disease. Methods--The clinical, biological, [...]

Published
2001

16. Factors determining a DMARD initiation in early inflammatory arthritis patients. The ESPOIR cohort study

Author

Lukas, C., Guillemin, F., Landewé, R., van der Heijde, D., Logeart, I., Fautrel, B., Daures, J. P., Combe, B., and Other departments

Subjects
musculoskeletal diseases
Abstract

To describe the rate and timing of DMARD start in patients with early inflammatory arthritis in France, and to determine the factors leading to this treatment start. The ESPOIR cohort study collects data on patients presenting with early arthritis. Baseline characteristics were assessed, and Cox regression analysis was performed to estimate the likelihood of starting DMARD treatment over time, adjusting for patient-, disease- and physician characteristics. Of the 775 analysed patients, 598 (77.2%) received at least 1 DMARD during the follow-up period, after a median time of 4.0 months. In general, a higher tender joint count, involvement of the hands, involvement of more than 3 joint groups, presence of abnormal CRP-levels or CCP-antibodies significantly increased the likelihood of being treated (p

Published
2009

17. Pharmacovigilance of drug allergy and hypersensitivity using the ENDA-DAHD database and the GA2LEN platform. The Galenda project

Author

Bousquet, P.-J. Demoly, P. Romano, A. Aberer, W. Bircher, A. Blanca, M. Brockow, K. Pichler, W. Torres, M.J. Terreehorst, I. Arnoux, B. Atanaskovic-Markovic, M. Barbaud, A. Bijl, A. Bonadonna, P. Burney, P.G. Caimmi, S. Canonica, G.W. Cernadas, J. Dahlen, B. Daures, J.-P. Fernandez, J. Gomes, E. Gueant, J.-L. Kowalski, M.L. Kvedariene, V. Mertes, P.-M. Martins, P. Nizankowska-Mogilnicka, E. Papadopoulos, N. Ponvert, C. Pirmohamed, M. Ring, J. Salapatas, M. Sanz, M.L. Szczeklik, A. Van Ganse, E. De Weck, A.L. Zuberbier, T. Merk, H.F. Sachs, B. Sidoroff, A.

Abstract

Nonallergic hypersensitivity and allergic reactions are part of the many different types of adverse drug reactions (ADRs). Databases exist for the collection of ADRs. Spontaneous reporting makes up the core data-generating system of pharmacovigilance, but there is a large under-estimation of allergy/hypersensitivity drug reactions. A specific database is therefore required for drug allergy and hypersensitivity using standard operating procedures (SOPs), as the diagnosis of drug allergy/hypersensitivity is difficult and current pharmacovigilance algorithms are insufficient. Although difficult, the diagnosis of drug allergy/hypersensitivity has been standardized by the European Network for Drug Allergy (ENDA) under the aegis of the European Academy of Allergology and Clinical Immunology and SOPs have been published. Based on ENDA and Global Allergy and Asthma European Network (GA2LEN, EU Framework Programme 6) SOPs, a Drug Allergy and Hypersensitivity Database (DAHD®) has been established under FileMaker® Pro 9. It is already available online in many different languages and can be accessed using a personal login. GA2LEN is a European network of 27 partners (16 countries) and 59 collaborating centres (26 countries), which can coordinate and implement the DAHD across Europe. The GA2LEN-ENDA-DAHD platform interacting with a pharmacovigilance network appears to be of great interest for the reporting of allergy/hypersensitivity ADRs in conjunction with other pharmacovigilance instruments. © 2009 The Authors.

Published
2009

18. The DESIR cohort: A 10-year follow-up of early inflammatory back pain in France: Study design and baseline characteristics of the 708 recruited patients

Author

Dougados, M., D'Agostino, Maria Antonietta, Benessiano, J., Berenbaum, F., Breban, M., Claudepierre, P., Combe, B., Dargent-Molina, P., Daures, J. -P., Fautrel, B., Feydy, A., Goupille, P., Leblanc, V., Logeart, I., Pham, T., Richette, P., Roux, C., Rudwaleit, M., Saraux, A., Treluyer, J. -M., van der Heijde, D., Wendling, D., D'Agostino M. A. (ORCID:0000-0002-5347-0060), Dougados, M., D'Agostino, Maria Antonietta, Benessiano, J., Berenbaum, F., Breban, M., Claudepierre, P., Combe, B., Dargent-Molina, P., Daures, J. -P., Fautrel, B., Feydy, A., Goupille, P., Leblanc, V., Logeart, I., Pham, T., Richette, P., Roux, C., Rudwaleit, M., Saraux, A., Treluyer, J. -M., van der Heijde, D., Wendling, D., and D'Agostino M. A. (ORCID:0000-0002-5347-0060)

Abstract

Objectives: The French Society of Rheumatology has initiated a large national multicenter, longitudinal, prospective follow-up of patients presenting with early inflammatory back pain in order to set up a database to facilitate several investigations on diagnosis, prognosis, epidemiology, pathogenesis and medico-economics in the field of early inflammatory back pain and spondyloarthritis. Methods: Patients were recruited if they had inflammatory back pain of more than 3. months and less than 3. years. Patients will be followed every 6. months during the first 2. years then every year during at least 5. years. Apart from information collected on a Case Report Form (demographics, disease activity, severity, co-morbidities, socio-economics, treatments, radiological and MRI evaluation of the spine and the pelvis according to the local investigators, and for some centers bone densitometry and ultrasonography of entheses), the digital X-rays and MRI of the spine and pelvis are stored using a specific software (Carestream) and the biological samples (DNA, RNA, sera, urines) are centralized at the Biological Resources Center (Bichat Hospital). Results: The recruitment period of the 708 patients (mean age: 34 ± 9. years, female 54%, HLA-B27 positive: 57%) in the 25 centers was 26. months (from December 2007 to April 2010). The modified New York criteria, Amor criteria, ESSG criteria and axial ASAS criteria were fulfilled by 26%, 77%, 76% and 67% of the patients at entry, respectively. A history or current symptoms suggestive of peripheral arthritis, acute anterior uveitis and inflammatory bowel disease were observed in 21%, 9% and 4% of the patients, respectively. The disease was active (BASDAI: 45 ± 20) despite an NSAID intake in 66% of the patients. Conclusion: This large cohort should facilitate the conduct of researches in different areas (clinical, medico-economics, translational) in order to improve our knowledge on the pathogenesis and natural history of axial spondyl

Published
2011

19. The CONSORT statement checklist in allergen-specific immunotherapy: a GA2LEN paper

Author

Bousquet, P J, Brozek, J, Bachert, C, Bieber, T, Bonini, S, Burney, P, Calderon, M, Canonica, G W, Compalati, E, Daures, J P, Delgado, L, Demoly, P, Dahl, R, Durham, S R, Kowalski, M L, Malling, H J, Merk, H, Papadopoulos, N, Passalacqua, G, Simon, H U, Worms, M, Wahn, U, Zuberbier, T, Schünemann, H J, Bousquet, J, Bousquet, P J, Brozek, J, Bachert, C, Bieber, T, Bonini, S, Burney, P, Calderon, M, Canonica, G W, Compalati, E, Daures, J P, Delgado, L, Demoly, P, Dahl, R, Durham, S R, Kowalski, M L, Malling, H J, Merk, H, Papadopoulos, N, Passalacqua, G, Simon, H U, Worms, M, Wahn, U, Zuberbier, T, Schünemann, H J, and Bousquet, J

Abstract

Udgivelsesdato: 2009-Dec, The methodology of randomized clinical trials is essential for the critical assessment and registration of therapeutic interventions. The CONSORT (Consolidated Standards of Reporting Trials) statement was developed to alleviate the problems arising from the inadequate reporting of randomized controlled trials. The present article reflects on the items that we believe should be included in the CONSORT checklist in the context of conducting and reporting trials in allergen-specific immunotherapy. Only randomized, blinded (in particular blinding of patients, health care providers, and outcome assessors), placebo-controlled Phase III studies in this article. Our analysis focuses on the definition of patients' inclusion and exclusion criteria, allergen standardization, primary, secondary and exploratory outcomes, reporting of adverse events and analysis.

Published
2009

28. Etoposide Plus Cisplatin With or Without the Combination of 4'-Epidoxorubicin Plus Cyclophosphamide in Treatment of Extensive Small-Cell Lung Cancer: a French Federation of Cancer Institutes Multicenter Phase III Randomized Study

Author

Pujol, J.-L., primary, Daures, J.-P., additional, Riviere, A., additional, Quoix, E., additional, Westeel, V., additional, Quantin, X., additional, Breton, J.-L., additional, Lemarie, E., additional, Poudenx, M., additional, Milleron, B., additional, Moro, D., additional, Debieuvre, D., additional, and Le Chevalier, T., additional

Published
2001
Full Text
View/download PDF

31. Environmental risk factors for non-Hodgkin's lymphoma: a population-based case-control study in Languedoc-Roussillon, France.

Author

Fabbro-Peray, Pascale, Daures, Jean-Pierre, Rossi, Jean-François, Fabbro-Peray, P, Daures, J P, and Rossi, J F

Abstract

Objective: To investigate the occupational and environmental risk factors related to non-Hodgkin's lymphoma (NHL).Methods: A case-control study was performed during the 1992-1996 period in Languedoc-Roussillon, southern France. Four hundred and forty-five cases of histologically diagnosed NHL were declared. One thousand and twenty-five randomly selected population controls were interviewed about their medical histories; occupational exposures, such as chemicals, pesticides, and electromagnetic radiation; and toxic habits.Results: The following factors were independently and significantly related to NHL as a result of the multivariate analysis: a previous hematopoietic malignancy (ORa = 11.5, 95% CI 2.4-55.4), a history of hives (ORa = 1.7, 95% CI 1.2-2.2), benzene exposure > 810 days (ORa = 4.6, 95% CI 1.1-19.2), daily welding (ORa = 2.5, 95% CI 1.2-5.0), and activity of radio operator (ORa = 3.1, 95% CI 1.4-6.6). To be an agricultural professional seemed slightly related to NHL in reference to non-professionals (ORa = 1.5, 95% CI 1.0-2.1). All of these results have also been adjusted for age, gender, education level, and urban setting.Conclusions: As some of the reported associations were based on a very small proportion of exposed subjects, further investigations are necessary to confirm our results. However, the findings suggest that factors related to altered immune functions such as a history of hematopoietic malignancy, history of hives, occupational exposure to benzene, or being an agricultural professional might increase the risk of NHL. Currently, underlying mechanisms for these associations are still unclear, and further investigations focused on interactions between immunity alterations and different chemicals would be of great interest. [ABSTRACT FROM AUTHOR]

Published
2001
Full Text
View/download PDF

32. Comparison of dietary assessment methods in a southern French population: use of weighed records, estimated-diet records and a food-frequency questionnaire.

Author

Bonifacj, C, Gerber, M, Scali, J, and Daures, J P

Abstract

Objective: The main objective of the study was to develop appropriate dietary assessment instruments for the French Mediterranean region and to validate the measurements they provide.Subjects and Methods: Three different assessment methods were submitted to a sample of 150 male and female volunteers. 98 completed the protocol, which consisted of a 4 d weighed dietary record (PETRA) and a 7 d estimated-diet record (S7) based on a check list and a set of photographs, both these records being completed once in each season of the year, and a semi-quantitative (standard portion) food-frequency questionnaire (FFQ) including questions eliciting socio-demographic and anthropometric data, which was completed once only. The days when PETRA was used to evaluate food consumption coincided with the first 4 d of S7 (S4).Results: Validation was based on nutrients and foods. Energy-adjusted Pearson correlation coefficients between S4 and PETRA ranged from 0.32 for vitamin E to 0.81 for vitamin C (mean: 0.65 for 21 nutrients). There was practically no misclassification in opposite extreme quartiles. Spearman correlation coefficients ranged from 0.63 for fish and sea-food to 0.90 for wine (mean: 0.76 for 16 food groups). There was practically no misclassification in opposite extreme quartiles. De-attenuated energy-adjusted Pearson correlation coefficients between FFQ and S7 ranged from 0.22 for proteins and monounsaturated fatty acids to 0.80 for iron (mean: 0.45). 10% or less of subjects were misclassified in opposite extreme quartiles (except for vitamin C, 12%). Spearman correlation coefficients ranged from 0.25 for green-yellow-red raw vegetables to 0.76 for wine (mean: 0.42). 8% or less of subjects were misclassified in opposite extreme quartiles (except for citrus fruit, 11%).Conclusions: Portion estimation using the set of photographs was validated by the correlation between S4 and PETRA for both nutrients and foods. The FFQ provides a reasonably reliable measure of macronutrient intake and a good measure of micronutrient intake when compared with the data in the literature. It performs less well for food intake. Better results can be achieved for FFQ: (i) by using the set of photographs instead of standard portions and (ii) by adding further questions on foods which are insufficiently covered. [ABSTRACT FROM AUTHOR]

Published
1997
Full Text
View/download PDF

34. Factors determining a DMARD initiation in early inflammatory arthritis patients. The ESPOIR cohort study.

Author

Lukas C, Guillemin F, Landewé R, van der Heijde D, Logeart I, Fautrel B, Daures JP, and Combe B

Subjects
Adult, Drug Administration Schedule, Female, France, Humans, Male, Middle Aged, Practice Patterns, Physicians', Proportional Hazards Models, Prospective Studies, Antirheumatic Agents administration & dosage, Arthritis, Rheumatoid drug therapy, Severity of Illness Index
Abstract

Background: To describe the rate and timing of DMARD start in patients with early inflammatory arthritis in France, and to determine the factors leading to this treatment start., Methods: The ESPOIR cohort study collects data on patients presenting with early arthritis. Baseline characteristics were assessed, and Cox regression analysis was performed to estimate the likelihood of starting DMARD treatment over time, adjusting for patient-, disease- and physician characteristics., Results: Of the 775 analysed patients, 598 (77.2%) received at least 1 DMARD during the follow-up period, after a median time of 4.0 months. In general, a higher tender joint count, involvement of the hands, involvement of more than 3 joint groups, presence of abnormal CRP-levels or CCP-antibodies significantly increased the likelihood of being treated (p<0.01 for all determinants), as well as a positive result on the bilateral foot-squeeze test (p<0.04). In addition, a significant hetero-geneity in therapeutic strategy across the 14 tested French regions was found: adjusted hazard ratios for DMARD start ranged from 1 to 2.15 (p<0.01), depending on the region where a patient was followed. For anti-CCP test and swollen joint count we demonstrated a statistically significant interaction with geographic region, implying that these tests are interpreted differently across regions. The same factors that increased the likelihood to start a DMARD were related to an earlier start., Conclusion: Rate and timing of treatment start with DMARDs in patients with early inflammatory arthritis in France is determined by well known clinical and biochemical variables. Apart from these variables, however, unknown and intangible factors that seem to cluster geographically are responsible for important variations in practice performance.

Published
2009

35. Mortality attributable to nosocomial infection: a cohort of patients with and without nosocomial infection in a French university hospital.

Author

Fabbro-Peray P, Sotto A, Defez C, Cazaban M, Molinari L, Pinède M, Mahamat A, and Daures JP

Subjects
Adult, Aged, Aged, 80 and over, Cohort Studies, Cross Infection epidemiology, Female, France epidemiology, Humans, Incidence, Length of Stay, Logistic Models, Male, Middle Aged, Prospective Studies, Risk Factors, Cross Infection mortality, Hospital Mortality, Hospitals, University
Abstract

Objective: To assess nosocomial infection (NI) as a risk factor for death and to estimate the population-attributable risk of death from NI., Design: A prospective cohort study of patients with and without NI., Setting: Nimes University Hospital, Nimes, France., Patients: Patients were recruited from May 7, 2001, to January 10, 2003. Patients in acute care and long-term care units who had NI were enrolled, and patients without NI were randomly selected and matched with patients with NI for age, sex, type of care (acute care vs. long-term care) and length of stay in hospital at study inclusion., Outcome Measures: Vital status within 60 days after study inclusion was assessed. We used conditional logistic regression to estimate the relative death risk from NI after adjusting for comorbidities, severity of the underlying disease, and all other confounding factors. The adjusted population-attributable risk was assessed using the Mantel-Haenszel method., Results: We recruited 1,914 patients with NI and 5,172 patients without NI. The median age of the patients with NI was 73 years; 1,045 (54.6%) were female. NI was associated with death within 60 days (adjusted odds ratio, 1.7 [95% confidence interval {CI}, 1.4-;2.2]; P<.001). The adjusted population-attributable risk of death for all sites of infection was 1.7% (95% CI, 1.4-2.1). If we consider the NI incidence to be 3%-6% in French hospitals, the population-attributable risk of death from NI would range from 2.1% (95% CI, 1.7%-2.5%) to 4.0% (95% CI, 3.3%-4.9%)., Conclusion: In this study, NI appeared to have a significant impact on mortality. Multicenter studies will be needed to confirm these results.

Published
2007
Full Text
View/download PDF

36. Radiological damage in patients with rheumatoid arthritis on sustained remission.

Author

Cohen G, Gossec L, Dougados M, Cantagrel A, Goupille P, Daures JP, Rincheval N, and Combe B

Subjects
Adult, Arthritis, Rheumatoid pathology, Arthritis, Rheumatoid physiopathology, Disease Progression, Female, Follow-Up Studies, Humans, Male, Middle Aged, Prognosis, Prospective Studies, Radiography, Remission Induction, Severity of Illness Index, Arthritis, Rheumatoid diagnostic imaging
Abstract

Objective: To assess the radiological damage progression in patients with recent rheumatoid arthritis in sustained remission., Methods: A cohort of 191 patients with active early (<1 year) rheumatoid arthritis was prospectively assessed at baseline, 3 and 5 years by the Disease Activity Score (DAS) and the Sharp-van der Heijde Score (SHS) for radiographic damage. Patients in remission (DAS<1.6) at the 3-year and 5-year time points were compared with patients with a persistently active rheumatoid arthritis by Wilcoxon's signed rank test., Results: 57 patients died, were lost to follow-up or had incomplete data; 30 (15.7% of those who completed) patients were in remission at 3 and 5 years. The SHS in these two groups was not significantly different at baseline (p = 0.15), but was lower in the remission group at 5 years (p = 0.0047). The median (IQR) radiographic score increased from 0.5 (0-7) at baseline to 2.5 (0-14) after 5 years for the remission group (p = 0.18) and from 2 (0-7) to 13 (3-29) in the group with active rheumatoid arthritis (p<0.001). 5 (16.7%) patients in remission had relevant progression of radiographic damage (ie, progression >4.1 points) and 6 (20%) presented new erosions in a previously unaffected joint between the third and the fifth years., Conclusion: Patients with early rheumatoid arthritis in sustained remission did not present statistically significant radiographic degradation at the group level; nevertheless, 16.7% of these patients did present degradation. Absence of progression should be part of the remission definition in rheumatoid arthritis.

Published
2007
Full Text
View/download PDF

37. Characteristics of patients with herpes zoster on presentation to practitioners in France.

Author

Chidiac C, Bruxelle J, Daures JP, Hoang-Xuan T, Morel P, Leplège A, El Hasnaoui A, and de Labareyre C

Subjects
Acute Disease, Adult, Aged, Aged, 80 and over, Dermatology, Family Practice, Female, France epidemiology, Humans, Incidence, Male, Middle Aged, Neuralgia epidemiology, Neuralgia physiopathology, Office Visits, Patient Care, Practice Patterns, Physicians', Prospective Studies, Surveys and Questionnaires, Herpes Zoster complications, Herpes Zoster epidemiology, Herpes Zoster physiopathology, Herpes Zoster therapy, Neuralgia etiology, Quality of Life
Abstract

There have been many epidemiological studies of chickenpox but only a few of herpes zoster. We report data from an observational study, conducted in France during a 1-year period, of 9038 patients who presented with acute herpes zoster (n = 8103) or postherpetic neuralgia (PHN; n = 935) at the office practices of 4635 general practitioners or dermatologists. The incidence of herpes zoster in France was found to be similar to that in the literature: from 1.4 to 4.8 cases per 1000 population per year. The patient profiles and clinical patterns were delineated, as well as the management decisions made according to the type of treating physician. The impact of herpes zoster on quality of life was evaluated on the basis of the Medical Outcome Study Short Form 36 (MOS SF 36) scale, which is widely used for assessing quality of life in the field of health. This study provides reference data on the substantial deterioration in quality of life associated with herpes zoster and PHN.

Published
2001
Full Text
View/download PDF

38. The 20210A allele of the prothrombin gene is an independent risk factor for perception deafness in patients with venous thromboembolic antecedents.

Author

Mercier E, Quere I, Chabert R, Lallemant JG, Daures JP, Berlan J, and Gris JP

Subjects
Adolescent, Adult, Aged, Alleles, Analysis of Variance, Autoantibodies blood, Deafness epidemiology, Female, Humans, Male, Middle Aged, Multivariate Analysis, Odds Ratio, Protein C Deficiency genetics, Protein S Deficiency genetics, Regression Analysis, Risk Factors, Venous Thrombosis epidemiology, Deafness complications, Deafness genetics, Prothrombin genetics, Thromboembolism complications, Thromboembolism genetics, Venous Thrombosis complications, Venous Thrombosis genetics
Published
1999

39. Non-invasive assessment of inspiratory muscle performance during exercise in patients with chronic heart failure.

Author

Vibarel N, Hayot M, Pellenc PM, Corret JL, Ramonatxo M, Daures JP, Leclercq F, Pons M, and Prefaut C

Subjects
Adult, Aged, Female, Humans, Lung Volume Measurements, Male, Middle Aged, Pulmonary Gas Exchange physiology, Reference Values, Work of Breathing physiology, Exercise Test, Heart Failure physiopathology, Inhalation physiology, Respiratory Muscles physiopathology
Abstract

Aims: The aim of this study was to assess inspiratory performance at rest and during exercise in patients with chronic heart failure in comparison with healthy controls using a non-invasive index: the tension-time index of inspiratory muscles (TTMUS)., Methods: We studied 13 patients with chronic heart failure (57 +/- 7 years) and 10 control subjects (58 +/- 6 years) at rest and during an incremental maximal exercise test. Measurements included breathing pattern (inspiratory time, total time of respiratory cycle, minute ventilation, tidal volume and respiratory frequency), mouth occlusion pressure and mean inspiratory pressure (calculated as follows: 5 x mouth occlusion pressure x inspiratory time). The maximal inspiratory pressure was measured at rest. TTMUS was calculated from the equation: TTMUS = PI/PIMAX x TI/TTOT, where PI/PIMAX is the ratio of mean inspiratory pressure to maximal inspiratory pressure and TI/TTOT is the ratio of mean inspiratory time to total time of the respiratory cycle., Results: At rest, the results in patients showed non-significantly higher mouth occlusion pressure, lower maximal inspiratory pressure (P < 0.001), and a higher ratio of mean inspiratory pressure to maximal inspiratory pressure (P < 0.01). There was no difference in the breathing pattern. TTMUS was thus significantly higher in the patients with chronic heart failure (P < 0.001). At maximal exercise (77 +/- 16 W for patients with chronic heart failure vs 142 +/- 27 W for controls, P < 0.001), the ratio of mean inspiratory time to total time of respiratory cycle, the mouth occlusion pressure and the ratio of mean inspiratory pressure to maximal inspiratory pressure were not different. TTMUS was thus comparable in the two groups. During exercise, at comparable workloads (20, 40 and 60 W), the patients showed higher mouth occlusion pressure (P < 0.01) and a higher ratio of mean inspiratory pressure to maximal inspiratory pressure (P < 0.001), whereas the ratio of mean inspiratory time to total time of the respiratory cycle was similar. TTMUS was thus higher in the patients at each workload (P < 0.05)., Conclusion: This study shows that the determination of TTMUS at rest and during exercise allows the observation of alterations in inspiratory muscle performance as a result of both reduced inspiratory strength, as measured by the maximal inspiratory pressure, and increased ventilatory drive, as reflected by the mouth occlusion pressure in patients with chronic heart failure. The non-invasiveness of this new index is an additional argument for its use in a clinical setting.

Published
1998
Full Text
View/download PDF

40. Increased generation of the arachidonic metabolites LTB4 and 5-HETE by human alveolar macrophages in patients with asthma: effect in vitro of nedocromil sodium.

Author

Damon M, Chavis C, Daures JP, Crastes de Paulet A, Michel FB, and Godard P

Subjects
Adolescent, Adult, Asthma drug therapy, Bronchoalveolar Lavage Fluid, Calcimycin pharmacology, Cells, Cultured, Chromatography, High Pressure Liquid, Female, Humans, Macrophages drug effects, Male, Middle Aged, Nedocromil, Pulmonary Alveoli, Quinolones therapeutic use, Zymosan pharmacology, Asthma metabolism, Hydroxyeicosatetraenoic Acids biosynthesis, Leukotriene B4 biosynthesis, Macrophages metabolism, Quinolones pharmacology
Abstract

Alveolar macrophages (AM) are the principal resident phagocytes in the human lung, and play a major role in local defence against environmental agents. It is now known that during asthma these cells take part in the amplification of the inflammatory mechanism. It has been demonstrated in vitro that they can be activated to generate leukotriene B4 (LTB4) and 5-hydroxyeicosatetraenoic acid (5-HETE), mediators with potent pharmacological properties. These two arachidonic metabolites were identified and quantified by reversed phase high performance liquid chromatography (HPLC) performed in cell suspensions, and in cell free supernatants. AM from asthmatics, after stimulation by the calcium ionophore A23187 or opsonized zymosan, released significantly (p less than 0.05) more LTB4 than those from healthy subjects. The increase in LTB4 release could be evidence for in vivo activation. On the other hand, the levels of 5-HETE in the AM from asthmatics were significantly (p less than 0.03) higher than those in cells from healthy subjects. This intracellular increase could be correlated with a greater migratory ability of these inflammatory macrophages, as observed for eosinophils. The clinical efficacy of nedocromil sodium may be partly related to the decreases in LTB4 releasability and intracellular 5-HETE levels observed only in AM from asthmatic patients.

Published
1989

Catalog

Books, media, physical & digital resources
See catalog results